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Abstract  
Context: MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its 
presence in cases of adverse reaction and death. Method: 43 cases of suspected synthetic cannabinoid 
ingestion were identified from patients presenting at an Emergency Department and from post-mortem 
casework. These were subjected to liquid-liquid extraction using tertiary-butyl methyl ether and quantitatively 
analysed by Electospray Ionisation Liquid Chromatography – tandem Mass Spectrometry. For positive samples, 
case and clinical details were sought and interrogated. Results: 11 samples were found positive for MDMB-
CHMICA. Concentrations found ranged from <1 – 22 ng/mL (mean: 6 ng/mL, median: 3 ng/mL). The age range 
was 15 – 44 years (mean: 26 years, median: 21 years), with the majority (82%) of positive results found in 
males. Clinical presentations included hypothermia, hypoglycaemia, syncope, recurrent vomiting, altered 
mental state and serotonin toxicity, with corresponding concentrations of MDMB-CHMICA as low as <1 ng/mL. 
Duration of hospitalisation ranged from 3 – 24 hours (mean: 12 hours, median: 8 hours). Discussion: The 
concentration range presented in this case series is indicative of MDMB-CHMICA having a high potency, as is 
known to be the case for other synthetic cannabinoid receptor agonists. The age range and gender 
representation were consistent with that reported for users of other drugs of this type. The clinical 
presentations observed were typical of synthetic cannabinoid receptor agonists and show the difficulties in 
identifying reactions potentially associated with drugs of this type. Conclusion: The range of MDMB-CHMICA 
concentrations in Emergency Department presentations (n=9) and post-mortem cases (n=2) was reported. No 
correlation between the concentration of this drug and clinical presentation or cause of death was reported in 
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this sample. However, the potential for harm associated with low concentrations of MDMB-CHMICA and the 
symptoms of toxicity being non-specific was highlighted. 
 
Introduction 
MDMB-CHMICA (methyl-2-(1-(cyclohexylmethyl)-1 H-indole-3-ylcarbonylamino)-3,3-dimethyl butanoate, 
Figure 1), is a novel indole-based compound in the ‘synthetic cannabinoid receptor agonist’ (SCRA) drug group. 
It has previously been erroneously referred to as MMB-CHMINACA. Based on SCRA nomenclature, however, 
‘CHMINACA’ indicates an indazole – rather than indole – structure, and ‘MMB-‘ indicates an isopropyl - rather 
than tertiary butyl - group. 
Formula Weight : 384.51
Formula : C23H32N2O3
MDMB-CHMICA
 
Figure 1 – Structure and chemical formula of MDMB-CHMICA 
The potential dangers of MDMB-CHMICA were first highlighted by the European Monitoring Centre for Drug 
and Drug Addiction Early Warning System (EMCDDA EWS) in December 2014 when seven non-fatal 
intoxications were linked to the drug in Austria
1
. Shortly after these adverse reactions, ten intoxications – four 
proving fatal – were reported in Sweden
1
. A third alert was issued in April 2015 reporting two deaths and three 
non-fatal intoxications linked to the drug in Germany
2
. Adverse reactions reported in the latter included 
seizures, severe motor impairment, and persistent vomiting; recorded causes of death included probable 
methadone intoxication and suffocation on aspirated gastric contents related to ethanol intoxication. In 
addition to this, details of seizures of the drug were given, including 40 kg en route from China to Spain seized 
in Luxembourg
2
. As of the beginning of May 2016, MDMB-CHMICA is not controlled in the U.K., but has been 
confirmed as an ingredient in several products including ‘AK47 Loaded’, ‘Manga Hot’, ‘Cloud 9-second 
Page 3 of 13 
 
generation-Mad Hatters-incense’, ‘Black Diamond’, ‘AKB48-F’, ‘PB-22-F’, ‘Sky High’ and ‘Sweet Leaf 
Obliteration’ in Europe
2, 3
. 
There is currently a paucity of data regarding the pharmacology and toxicology of MDMB-CHMICA, but case 
reports describe vomiting, seizures, and psychological distress as possible sequlae from ingestion. A case 
report from Norway implicates an ante-mortem serum concentration of 1.4 ng/mL MDMB-CHMICA as the 
probable cause of death, although mirtazapine (5.3 ng/mL), Δ
9
-tetrahydrocannabinol (Δ
9
-THC, 1.5 ng/mL), and 
cetirizine (not quantified) were also present
4
.  
The first reports of adverse reactions to MDMB-CHMICA in the U.K. were reported in the summer of 2015 with 
one in North Wales and one in Glasgow
5, 6
. In response to this the authors developed and validated an LC-
MS/MS method, with a simple liquid-liquid extraction for the quantification of MDMB-CHMICA in whole blood.  
 
Materials and Methods 
Materials 
MDMB-CHMICA was purchased from Chiron (Trondheim, Norway) and JWH-200-d5 was purchased from 
LGC Standards (Teddington, U.K.). Phosphate buffer (pH 6, 0.1M) was prepared in-house from disodium 
hydrogen orthophosphate anhydrous and sodium dihydrogen orthophosphate dihydrate from Fisher Scientific 
(Loughborough, U.K.) and deionised water produced from a Purite (Thame, U.K.) deionised water system. 
Tertiary methyl butyl ether (tBME) and ammonium acetate were purchased from Sigma Aldrich (Gillingham, 
U.K.). Methanol and acetonitrile, both HPLC grade, and formic acid were obtained from VWR (Lutterworth, 
Leicestershire, U.K.). Blood products were purchased from the Scottish National Blood Transfusion Service 
(SNBTS) based at Gartnavel Hospital (Glasgow, U.K.).  
 
Methods 
Sample Collection and Data Analysis 
The laboratory at Forensic Medicine and Science (FMS) provides post-mortem (PM) toxicology services 
for the cities of Glasgow, Edinburgh and Dundee and their surrounding regions, as well as an ongoing research 
project analysing Emergency Department (ED) admission samples for Novel Psychoactive Substances (NPS). 
Between the 1
st
 of September and the 9
th
 of December 2015, 43 cases were submitted for MDMB-CHMICA 
analysis to the laboratory, comprising 17 PM submissions and 26 cases from the ED of Glasgow Royal 
Page 4 of 13 
 
Infirmary. The decision to conduct MDMB-CHMICA analysis on a sample was made on case circumstances 
suggestive of SCRA use. It is acknowledged that in some circumstances case details may have been misleading 
or lacking leading to incorrect inclusion or exclusion of cases.  
Unpreserved blood samples were obtained either by collection at autopsy for PM cases, or during the clinical 
management of ED patients. The NHS Greater Glasgow and Clyde Research and Development Committee 
advised ethical approval was not required for this service development study. With regards to the PM cases, 
the medical histories of the deceased and basic PM findings were reviewed. Prior to toxicological analysis, only 
limited presenting symptoms and potential substances ingested were known for ED samples.  
On receipt at Forensic Medicine and Science, the specimens were stored between 2 – 8 °C prior to analysis. 
These were submitted for MDMB-CHMICA analysis if the case circumstances suggested that SCRAs may have 
been used prior to death or hospital treatment. The additional analyses conducted were dependant on case 
circumstances and available sample volume, and included alcohol and the most prevalent prescription and 
recreational drugs.  
On completion of toxicological analysis, each case was reviewed in terms of gender and age of individual, other 
toxicological findings, drug product ingested (if noted) and any other relevant circumstantial information. 
Where the case was a PM investigation, the assigned cause of death was also noted.  
 
Toxicological Analysis 
MDMB-CHMICA was detected and quantified using an Agilent 1260 Infinity Liquid Chromatography (LC) 
system coupled with tandem Mass Spectrometry (MS; ABSciex 3200 QTRAP® instrument). A calibration range 
of 1 – 100 ng/mL MDMB-CHMICA was employed. Extraction of the analyte plus internal standard (I.S., JWH-
200-d5 at 25 ng/mL) was undertaken through a liquid-liquid extraction process, by adding tBME (2 mL) to 100 
µL blood sample plus 2 mL pH 6.0, 0.1 M phosphate buffer. Chromatographic separation took place on a 
Phenomenex Gemini C18 column (150 mm x 2.0 mm, 5 μm) fitted with a guard column of the same packing 
material, held at 40 °C, and using a mobile phase flow rate of 300 µL/min. The mobile phase was run 
isocratically and was composed of 0.1% formic acid and 2 mM ammonium acetate in 20% deionised H2O and 
80% methanol. MS detection was conducted using positive Electrospray Ionisation (ESI) with multi-reaction 
monitoring (MRM). The transitions monitored for MDMB-CHMICA were m/z 385 → 240 for the quantification 
transition and m/z 385 → 144 and 116 (qualifier transitions), with m/z 390 → 155 for the I.S. 
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The method was validated according to the following criteria: linearity with 1/x weighting was assessed by 
analysing calibrators of 1, 5, 10, 25, 50 and 100 ng/mL, evaluating the linear model and correlation co-efficient. 
Selectivity was determined by the absence of a MDMB-CHMICA peak in MDMB-CHMICA-free samples. The 
lower limit of quantification (LLOQ) was defined as the lowest calibrator, ensuring a signal-to-noise ratio of at 
least 10:1. The limit of detection (LOD) was designated as the lowest concentration affording a signal-to-noise 
ratio of 3:1. Inter- and intra-day accuracy and precision were determined at 10 and 42 ng/mL, with accuracy 
defined by the ratio of the mean actual concentration of triplicate standards to their expected concentration 
multiplied by 100, and the %CV of the triplicate results taken as the precision. Process efficiency was 
determined at 50 ng/mL by comparison of the mean peak area of calibrators extracted from blank blood in 
triplicate to those of an unextracted solution of equivalent concentration. Matrix effects were assessed at 50 
ng/mL using the Matuszewski method
7
 and 6 distinct sources of blank blood.  
 
Results  
Toxicological Analysis 
Linearity was assessed over the calibration range 1 – 100 ng/mL and established (R
2
 >0.99) using 1/x 
weighted regression. The LLOQ was assigned as the lowest calibrator (1 ng/mL), with LOD determined to be 
0.5 ng/mL. Mean inter-day accuracy was found to be 102 and 104% at 10 and 42 ng/mL respectively; and the 
mean precision at the same concentrations was ≤8.3% and ≤5.3% respectively. Mean intra-day precision was 
found to be ≤4.7% at 10 ng/mL and ≤3.7% at 42 ng/mL; and the mean accuracy was calculated as 96% and 
108% for 10 ng/mL and 42 ng/mL respectively. Process efficiency was calculated as 90% at 50 ng/mL. Slight ion 
enhancement was observed when the matrix effects were assessed, the most significant of these being an 
extracted peak area at 116 % of the unextracted equivalent.  
The ion transitions employed in MDMB-CHMICA analysis were found to be identical to those used for another 
SCRA, BB-22 (1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester), which is similar structurally 
and shares the precursor ion m/z 385. In addition to this, these drugs were not resolved chromatographically 
on the MP system in use. In order to distinguish between the two drugs, the ratio of the quantitation transition 
(m/z 385  240) to the qualifier transition (m/z 385  116) was calculated and this value differed sufficiently 
to allow distinction. However, it is important to bear in mind the resemblance of these substances in terms of 
analytical behaviour. 
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Analysis of Case Samples 
Between the 1
st
 of September and the 9
th
 of December 2015, 43 blood samples were submitted for 
MDMB-CHMICA analysis, comprising 17 PM cases and 26 ED cases, with a total of 11 found to be positive for 
the drug. Concentrations ranged from <1 to 22 ng/mL, with a mean of 6 ng/mL and median of 3 ng/mL. These 
cases are detailed in Table 1 and Table 2 for ED and PM cases respectively. With regards to the cases negative 
for this analyte, generally these were found positive for other drugs which would account for the observed 
symptoms. This, however, falls outside the scope of this study. 
The age range was 15 – 44 years (mean: 26, median: 21). The gender split was 82% males to 18% females.  
The most prevalent substance found in combination with MDMB-CHMICA in the samples tested was alcohol, 
which was present in 60% of MDMB-CHMICA-positive cases at concentrations from 79 to 237 mg/dL (mean: 
163, median: 178). It should be noted that alcohol analysis was not conducted in case 10, as it was not 
requested by the pathologist.  The main active component of cannabis, Δ
9
-THC, or its metabolite, 11-nor-Δ
9
-
THC-COOH, was also present in 27% of cases.  
 
The predominant clinical features on presentation at ED were syncope, present in 67% of ED cases, and 
recurrent vomiting, present in 33% of ED cases.  With the exception of cases 1, 5 and 8 body temperatures 
were indicative of hypothermia with mean and median body temperatures of 35.1 °C and 34.8 °C respectively 
(range: 33.0 – 38.5 °C).  Blood glucose concentrations, where noted, ranged from 3.3 – 8.5 mmol/L (mean and 
median both 5.5) with 75% within the range indicative of fasting. Heart rates ranged from 54 – 150 bpm 
(mean: 112, median: 120) with sinus tachycardia being the most common presentation (78%).  Systolic blood 
pressure (SBP) ranged from 100 – 148 (mean: 118, median: 116), with the diastolic equivalent (DBP) ranging 
from 57 – 91 (mean: 71, median: 65).  Glasgow Coma Scores (GCS) ranged from 4/15 – 15/15 with the mean 
and median being 12/15 and 14/15 respectively. Duration of hospitalisation varied, ranging between 3 – 24 
hours (mean: 12 hours, median: 8 hours).  
 
The cause of death noted for case number 10 was suicidal hanging; the individual had a history of poor 
mental health.  
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With regards to case 11, the cause of death was recorded as complications of chronic alcohol abuse and acute 
alcohol toxicity. 
 
Discussion  
The age range and gender representation  is in-keeping with other studies where ‘young’ males or males 
in their early 20s have been the most common demographic to be encountered by medical staff treating 
symptoms of synthetic cannabis use
8, 9
. Of note is the consumption of the drug by an individual under 16 (case 
4); there is a lack of understanding as to how MDMB-CHMICA use may affect development either 
physiologically or mentally.  
It is not possible to compare the positivity rate between PM samples and ED admissions due to the non-
standardised inclusion criteria for MDMB-CHMICA analysis. The effects of the interval between death and PM, 
PM sampling and analysis, and the degraded nature of PM blood on MDMB-CHMICA concentrations is 
unknown, and these complications were unlikely to be present to the same extent in the ED cases. An 
additional concern is the limited information available regarding potential metabolites of MDMB-CHMICA and 
no potential metabolites were included in the analytical method presented here. 
The presence of alcohol in 60% of cases is unsurprising given its prevalence in Scottish society. Case numbers 
6, 7 and 11 exhibit notably high alcohol concentrations; the symptoms of which may themselves require 
medical intervention. Literature has suggested that users of SCRAs are likely to have been or be current 
cannabis users, and SCRAs may be co-administered with cannabis by being smoked in the same ‘joint’
10
 The 
presence of cannabinoids or SCRAs in cases 2, 3, 6, 8 and 9 is indicative of these substances having been 
ingested within a similar timescale to or concurrently with MDMB-CHMICA. 
With regards to cases 1, 8 and 9, no benzodiazepines were prescribed or used in the treatment of these 
individuals. The presence of diazepam and/or desmethyldiazepam was due to illicit consumption.  
The drug products named, where provided, have largely been found to contain MDMB-CHMICA
3
. However it is 
not uncommon for drug product packaging to be misleading or incorrect in terms of ingredients, so this 
information should be treated with caution. 
While little is known currently about the potential short- and long-term psychological effects of SCRAs, there is 
evidence of new psychotic phenomena exhibiting after SCRA use in individuals already undergoing treatment 
for psychiatric disorders
8, 11
. Known effects of SCRA use are hallucinations, psychosis, anxiety and panic attacks, 
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and it has been suggested that these may be due to disturbed dopaminergic neurotransmission; also a 
hypothesis for the aetiology of schizophrenia
12
.  
Recent media reports have focussed on the apparent prevalence of use of “legal highs” - specifically SCRAs - 
within prisons, and the Prison and Probation Ombudsman for England and Wales has recently issued a report 
into fatal cases of “legal high” use
13-15
. Some of these incidents included the use of SCRAs, although no deaths 
mentioned in this report suggest SCRAs intoxication as a direct cause of death, and the specific drug is not 
mentioned. The types of behaviours associated with SCRA use, some of which were observed in these cases, 
would be a troubling occurrence in prison settings, both in terms of safety of the individual under the influence 
of the drug and those managing the situation. Indeed, the U.K. Government intends to make possession of 
MDMB-CHMICA and other drugs covered by the Psychoactive Substances Bill an offence whilst in a custodial 
institution; possession of such a drug out in any other setting will not be prohibited
16
.  
A recent study analysed the urine of ED patients for Novel Psychoactive Substances (NPS), but acknowledged a 
limitation that SCRA drugs were not included within the scope of testing
17
.  
 
The observation of hypothermia was believed to be reflective of the drug’s action, as all cases occurred 
during the summer months, when the ambient temperature was around 12 °C, and the patients were brought 
to hospital relatively quickly after ingestion of the drug. 
With regards to case 2, the relatively high concentration of MDMB-CHMICA, along with other SCRAs, appeared 
to have contributed to the recurrent hypoglycaemia, necessitating an intravenous infusion of dextrose, with 
additional boluses. This pharmacological action is supported, as the patient was found to be smoking the 
product within the hospital ward during the episodes of profound hypoglycaemia whilst on a dextrose 
infusion. The overall majority of ED cases (75%) exhibited blood glucose concentrations indicative of fasting. 
Whilst this could be a symptom of generally poor self-care among drug users, it is an interesting finding as 
previous studies have linked the ingestion of synthetic cannabinoids to hyperglycaemia 
18,19
. 
Heart rates were generally tachycardic (78%) while BP were generally unremarkable. Case number 1 exhibited 
a heart rate of 150 bpm and was hypertensive. Case 5 also exhibited hypertension, with a BP of 148/91. Case 7 
was the only other case outside of the normal BP range, at a pre-hypertensive level of 134/76. 
It was of concern that very low concentrations of MDMB-CHMICA were capable of inducing acute toxicity 
manifesting as a dissociative state (case 9) and clinical features of serotonin toxicity (case 7), suggestive of high 
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potency. Additional drugs or alcohol present in these cases, idiosyncratic reactions, and/or the presence of 
active MDMB-CHMICA metabolites must be acknowledged as potential contributing factors to adverse effects. 
It is not surprising, therefore, that overall the concentrations of MDMB-CHMICA observed do not appear to 
have any correlation to blood glucose concentration, GCS score, heart rate, blood pressure, or duration of 
hospitalisation in this case series. However, there does seem to be evidence of the drug causing a decrease in 
body temperature, which may be of interest in further studies. 
With regards to treatment of individuals presenting at the ED, this was administered on a symptomatic basis 
and guided by local policy. Necessary treatment included the administration of antibiotics due to aspirated 
vomitus (case 1), intravenous dextrose administration (case 2), urinary catheterisation (case 7), sedation and 
the administration of cooled fluids (both case 5).  
 
Neither of the PM cases in this case series had causes of death attributable to MDMB-CHMICA toxicity. It 
is expected that further elucidation of MDMB-CHMICA pharmacology will increase understanding of the 
potential for this drug to contribute to mortality.  
 
Limitations 
The authors acknowledge the small scale of the case series, which was determined by the number of 
cases submitted for MDMB-CHMICA analysis and the resulting positive cases. The number of cases submitted 
for analysis was determined by case information, which was limited in some cases and may have been 
inaccurate due to the illicit nature of the drug and mental state of the individual undergoing emergency 
treatment. It is possible that the inclusion of metabolites of MDMB-CHMICA would have increased the window 
of detection for the drug, and additional positive cases may have resulted. The metabolism of this drug is, 
however, not understood and no reference standards for potential metabolites are commercially available. 
This is therefore acknowledged as a limitation of this study. 
 
Conclusion 
We have presented a series of cases positive for MDMB-CHMICA and the relevant clinical findings, 
confirming that this drug was used within the Scottish population. Whilst no correlation of MDMB-CHMICA 
concentration to clinical effects can be confirmed from this limited case series, it was noted that adverse 
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symptoms were present in a case (case 5) exhibiting an MDMB-CHMICA concentration of <1 ng/mL where no 
other drugs or alcohol were detected.  
 
Acknowledgements 
The authors would like to thank the staff of the Emergency Department at Glasgow Royal Infirmary for 
sample collection, and Claire Parks and Lauren O’Connor for their work to complete the additional 
toxicological analyses on these samples.  
The authors are also very grateful to the Scottish Government for the financial contribution provided towards 
the funding for some of this work.  
 
Declarations of Interest 
The authors report no declarations of interest. 
 
References 
1. EMCDDA. EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 
2005/387/JHA Lisbon: EMCDDA, 2015. 
2. Christie R. EU Early Warning System Alert: 2 deaths and 3 non-fatal intoxications in Germany 
associated with MDMB-CHMICA (methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-ylcarbonylamino)-3,3-
dimethylbutanoate). Luxembourg: EMCDDA, 2015. 
3. Public Health Wales. Welsh Emerging Drugs & Identification of Novel Substances Project 2014 [online] 
Available at: http://www.wedinos.org/db/samples. Accessed 02 October 2015. 
4. Westin AA, Frost J, Brede WR, Gundersen POM, Einvik S, Aarset H, et al. Sudden Cardiac Death 
Following Use of the Synthetic Cannabinoid MDMB-CHMICA. Journal of Analytical Toxicology. 
2015;40:86-7. 
5. Hospitalisation From Synthetic Cannabinoid MMB-CHMINACA [press release]. Wales: NHS Wales 
2015. 
6. Simpson K. Drug Trend Bulletin Issue 2. Police Scotland, 2015. 
7. Matuszewski B, Constanzer M, Chavez-Eng C. Strategies for the assessment of matrix effect in 
quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry. 2003;75:3019-30. 
8. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from 
the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology. 2015;54:1-13. 
9. Mills B, Yepes A, Nugent K. Synthetic Cannabinoids. Am J Med Sci. 2015;350:59-62. 
Page 11 of 13 
 
10. Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following 
consumption of cannabis or synthetic cannabinoids in a large global sample. Journal of 
Psychopharmacology. 2015;29:698-703. 
11. Celofiga A, Koprivsek J, Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: 
case series. J Dual Diagn. 2014;10:168-73. 
12. Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological Findings of Synthetic Cannabinoids in 
Recreational Users. Journal of Analytical Toxicology. 2013;37:534-41. 
13. BBC News. Legal highs: Call to investigate link to prison deaths [online] Available at: 
http://www.bbc.co.uk/news/uk-england-34385206. Accessed 02 October 2015. 
14. The Economist. At Her Majesty’s pleasure [online] Available at: 
http://www.economist.com/news/britain/21660148-legal-highs-are-rife-jails-new-laws-wont-help-
much-her-majestys-pleasure. Accessed 05 August 2015. 
15. Prison and Probation Ombudsman. Learning Lessons Bulletin Fatal Incident Investigations Number 9 
2015. 
16. Psychoactive Substances Bill, (2015) [online] Available at 
http://www.publications.parliament.uk/pa/bills/cbill/2015-2016/0088/cbill_2015-
20160088_en_1.htm. Accessed 15 January 2016. 
17. Lowe, D.J., Torrance, H.J., Ireland, A.J., Bloeck, F. and Stevenson, R. SODAS: Surveillance of Drugs of 
Abuse Study. European Journal of Emergency Medicine. 2015;15:16. 
18. Seely, K.A., Prather, P.L., James, L.P., Moran, J.H. Marijuana-based drugs: innovative therapeutics or 
designer drugs of abuse? Molecular interventions. 2011;11(1):36. 
19. Hess, C, Stockhausen, S, Kernbach-Wighton, G, Madea, B. Death due to diabetic ketoacidosis: 
Induction by the consumption of synthetic cannabinoids? Forensic Science International. 
2015;257:e6-11. 
 
Page 12 of 13 
 
 
 
Table 1 – Details of ED cases positive for MDMB-CHMICA 
Case Gender 
Age 
(years) 
MDMB-
CHMICA 
Conc. 
(ng/mL) 
Ethanol 
Conc. 
(mg/dL) 
Other Substances 
Present (mg/L)  
Estimated time 
from use to 
sampling  
Circumstances/Clinical Presentation 
1 F 20 5 130 Diazepam (0.075)  1 hour 
Ingestion of 'Sweet Leaf' product. GCS§ 4/15. Temp. 37.5 °C. Glucose 7.1 mmol/L. Heart rate 150 
bpm sinus tachycardia, BP║ 130/90. Persistent vomiting, syncope, respiratory acidosis (Venous 
blood gases: [H+] 67#, [La−] 1.9**, [HCO3
-] 25††, BE -4.7‡‡). 8 hours hospitalisation. 
2 M 41 22 ND 
5F-AKB48 (present), 5F-
PB-22 (present), 5F-PB-
22 3-carboxyindole 
metabolite (present) 
1 hour Ingestion of 'Black Mamba' product. GCS
§ 15/15. Temp. 33 °C. Glucose 3.3 mmol/L. Heart rate 40 
bpm sinus bradycardia, BP║ 110/60. Syncope, recurrent hypoglycaemia (12 hours), background of 
alcoholism, routine bloods normal. 24 hours hospitalisation. 
3 M 25 <5* 80 
5F-AKB48 (present), 11-
nor-Δ9-THC-COOH‡ (4 
ng/mL) 
>3 hours 
Ingestion of 'Sweet Leaf' and 'Saint Row' products. GCS§ 15/15. Temp. 35.2 °C. Glucose 3.9 mmol/L. 
Heart rate 94 bpm sinus tachycardia, BP║ 102/65. Syncope, vomiting, routine bloods normal. 3 
hours hospitalisation. 
4 M 15 <2* ND ND 1 hour 
Ingestion of 'Red Exodus'. GCS§ 13/15. Temp. 36 °C. Glucose 4.3 mmol/L. Heart rate 54 bpm sinus 
bradycardia, BP║ 100/57. Persistent vomiting, syncope, routine bloods normal. 22 hours 
hospitalisation. 
5 M 21 <1 ND ND  >24 hours 
Admitted to ED with acute behavioural disturbance and drug-induced psychosis. Spontaneous 
urinating/defecating, thought disorder, aggression. Temp. 38.5 °C. Heart rate 150 bpm, BP║ 148/91. 
Routine bloods normal. 2 hours hospitalisation. 
6 F 16 <1 225 
11-nor-Δ9-THC-COOH‡ (9 
ng/mL)  
1 hour 
Ingestion of 'Red Exodus'. GCS§ 14/15. Temp. 33.9 °C. Glucose 5.6 mmol/L. Heart rate 130 bpm 
sinus tachycardia, BP║ 118/74. Combative, acute behavioural disturbance, routine bloods normal. 3 
hours hospitalisation. 
7 M 18 2 229 ND  40 min. 
Ingestion of 'Damnation'. GCS§ 7/15. Temp. 34.8 °C. Glucose 5.9 mmol/L. Heart rate 120 sinus 
tachycardia, BP║ 134/76. Serotonin toxicity (clonus, hyperreflexia), acute behavioural disturbance, 
mild metabolic acidosis (Venous blood gases: [H+] 54#, [La−] 3.2**, [HCO3
-] 23††, BE -4.8‡‡). 19 hours 
hospitalisation. 
8 M 24 1 ND 
Δ9-THC¶ (5 ng/mL), 11-
nor-Δ9-THC-COOH‡ (35 
ng/mL), diazepam (0.2), 
desmethyldiazepam 
(0.13), morphine (<0.05)  
4 hours Ingestion of 'Obliteration'. GCS
§ 14/15. Temp. 37.2 °C .Glucose 5.3 mmol/L. Heart rate 108 sinus 
tachycardia, BP║ 116/61. Syncope, routine bloods normal. 17 hours hospitalisation. 
9 M 20 4 79 
Diazepam (0.28), 
desmethyldiazepam 
(0.34), 11-nor-Δ9-THC-
COOH‡ (23 ng/mL)  
2 hours Ingestion of 'K2'. GCS
§ 12/15. Temp. 34.2 °C. Glucose  8.5 mmol/L. Heart rate 130 sinus tachycardia, 
BP║ 100/63. Syncope, dissociative state, confused. 7 hours hospitalisation. 
ND Non-Detected; NA Not analysed 
* LOD amended due to limited sample volume      † β-hydroxybutyrate      ‡ 11-Nor-Δ9-Tetrahydrocannabinol carboxylic acid      ¶ Δ9-Tetrahydrocannabinol      §  Glasgow Coma Scale      ║ Blood Pressure  
#  Hydrogen ions (nmol/L)      ** Lactate (mmol/L)       †† Bicarbonate (mmol/L)      ‡‡ Base Excess (mmol/L) 
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Table 2 - Details of PM cases positive for MDMB-CHMICA 
Case  Gender Age (years) 
MDMB-CHMICA 
Conc. (ng/mL) 
Ethanol Conc. 
(mg/dL) 
Other Substances Present (mg/L)  Circumstances/Clinical Presentation 
10 M 44 1 NA Amitriptyline (0.13)  Found dead by hanging. 
11 M 38 <1 237 Acetone (<100), BHB† (249)   History of alcoholism: found dead at home. 
NA Not analysed      † β-hydroxybutyrate 
 
